Lead Product(s) : GB18
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
Details : GB18 is an innovative biologic product and a nanobody targeting GDF-15 developed for the treatment of cancer cachexia.
Product Name : GB18
Product Type : Antibody
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : GB18
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy
Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : $1,650.0 million
March 12, 2025
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Lead Product(s) : ARO-ALK7
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Details : ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue. It is being evaluated for the treatment of obesity.
Product Name : ARO-ALK7
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : ARO-ALK7
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARO-ALK7
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Seeks Approval for ARO-ALK7 Phase 1/2a Trial in Obesity Treatment
Details : ARO-ALK7 is an ACVR1C gene expression silencer, in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle, in obese patients
Product Name : ARO-ALK7
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : ARO-ALK7
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolexis Advances AMPK Agonists for Weight Loss in Preclinical Development
Details : BLX 0871 is an AMPK activator, which is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.
Product Name : BLX 0871
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.
Product Name : RES-010
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : ARO-INHBE
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Files for Phase 1/2a Study Clearance of ARO-INHBE for Obesity
Details : ARO-INHBE, a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Product Name : ARO-INHBE
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : ARO-INHBE
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antag Receives FDA Clearance For IND Application For AT-7687
Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.
Product Name : AT-7687
Product Type : Peptide
Upfront Cash : Inapplicable
September 10, 2024
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enobosarm,Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Veru Submits IND for Enobosarm-GLP-1 to Prevent Muscle Loss
Details : VERU-024 (enobosarm) is a novel selective AR modulator which is beig evaluated in preclinical studies to prevent muscle loss while augmenting fat loss in combination with GLP-1 drugs for weight loss.
Product Name : VERU-024
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Enobosarm,Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Versant Ventures
Deal Size : $84.0 million
Deal Type : Series A Financing
Antag Therapeutics Announces €80 Million Series A Financing
Details : The proceeds from the financing will be used for the development of Antag's lead molecule AT-7687. It is a peptide designed to be co-administrated with current or future obesity therapies.
Product Name : AT-7687
Product Type : Peptide
Upfront Cash : Undisclosed
April 12, 2024
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Versant Ventures
Deal Size : $84.0 million
Deal Type : Series A Financing